TOWA PHARMACEUTICAL CO.,LTD. (4553) Annual Securities Report & Filings
TSE sector: Pharmaceutical. Annual and semi-annual securities reports are filed with the Financial Services Agency through EDINET. Earnings reports and results presentations are on the Latest Updates page.
Company profile
- Fiscal year end： March 31
- Paid-in capital： ¥4,717M
- Consolidated： Yes
- EDINET code： E00974
- Corporate number： 4120001157872
Financial Highlights
| Actual | Prior year | Change | |
|---|---|---|---|
| Net sales | 714億円 | 651億円 | +9.6% |
| Operating income | 65億円 | 52億円 | +25.2% |
| Ordinary income | 79億円 | 40億円 | +100.9% |
| Profit | 55億円 | 25億円 | +120.1% |
| EPS (JPY) | 112.36 | — | — |
Source: Earnings report (TDnet, disclosed 2026-08-06)
Financial history
Show table：Income statement
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 55.2 | 61.4 | 71.5 | 82.1 | 85.0 | 93.4 | 105 | 110 | 155 | 166 | 209 | 228 | 260 | 274 |
| Gross profit | — | — | — | 41.9 | 39.0 | 43.0 | 48.4 | 50.6 | 65.5 | 70.2 | 72.7 | 81.4 | 94.7 | 99.1 |
| Operating income | — | — | — | 11.1 | 6.87 | 11.6 | 16.0 | 16.1 | 19.9 | 19.2 | 5.51 | 17.6 | 23.2 | 23.1 |
| Ordinary income | 9.54 | 8.83 | 15.4 | 10.2 | 7.42 | 11.7 | 18.9 | 21.0 | 18.7 | 22.7 | 5.14 | 24.5 | 26.1 | 28.1 |
| Pre-tax income | — | — | — | 9.90 | 7.24 | 9.83 | 18.9 | 20.7 | 18.7 | 22.3 | 4.61 | 24.5 | 26.3 | 13.2 |
| Net income | 6.20 | 5.99 | 11.1 | 7.68 | 5.58 | 6.50 | 13.5 | 14.5 | 14.0 | 15.9 | 2.20 | 16.2 | 19.0 | 5.25 |
Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.
Show table：Balance sheet
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets | — | — | — | 95.1 | 86.5 | 94.2 | 108 | 122 | 137 | 167 | 183 | 218 | 247 | 267 |
| Total assets | 89.7 | 103 | 121 | 157 | 165 | 177 | 189 | 230 | 246 | 332 | 371 | 431 | 471 | 475 |
| Current liabilities | — | — | — | 31.3 | 34.6 | 35.9 | 37.2 | 70.2 | 51.5 | 115 | 78.5 | 80.1 | 87.9 | 96.9 |
| Total liabilities | 34.1 | 43.2 | 51.1 | 86.3 | 90.3 | 97.3 | 97.0 | 125 | 129 | 200 | 234 | 275 | 299 | 297 |
| Equity | 55.6 | 60.1 | 70.0 | 70.6 | 74.9 | 79.9 | 91.8 | 105 | 117 | 132 | 137 | 156 | 172 | 178 |
Positive = cash in, negative = cash out.
Show table：Cash flow statement
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 8.65 | 8.14 | 8.04 | 3.73 | 10.2 | 19.2 | 19.0 | 19.2 | 12.0 | 22.1 | 2.54 | 8.21 | 23.4 | 30.4 |
| Investing | -11.3 | -11.3 | -8.23 | -19.0 | -22.2 | -20.1 | -3.99 | -39.5 | -9.10 | -59.7 | -30.3 | -40.4 | -31.3 | -25.7 |
| Financing | 2.79 | 3.53 | 0.24 | 28.0 | -0.09 | 4.67 | -0.81 | 11.8 | 0.18 | 46.5 | 17.5 | 35.4 | 21.6 | -6.83 |
| Cash at period end | 3.99 | 4.68 | 5.21 | 18.5 | 7.11 | 11.5 | 26.6 | 18.7 | 22.9 | 32.8 | 24.3 | 29.6 | 45.5 | 44.8 |
Gross, operating and net margin = the respective profit ÷ revenue.
Show table：Profitability
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | 51.0% | 46.0% | 46.1% | 46.0% | 45.9% | 42.3% | 42.4% | 34.8% | 35.7% | 36.5% | 36.2% |
| Operating margin | — | — | — | 13.6% | 8.1% | 12.5% | 15.2% | 14.6% | 12.9% | 11.6% | 2.6% | 7.7% | 8.9% | 8.4% |
| Net margin | 11.2% | 9.8% | 15.6% | 9.4% | 6.6% | 7.0% | 12.8% | 13.1% | 9.0% | 9.6% | 1.1% | 7.1% | 7.3% | 1.9% |
ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.
Show table：Returns & leverage
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.2% | 10.3% | 17.1% | 10.9% | 7.7% | 8.4% | 15.7% | 14.8% | 12.6% | 12.8% | 1.6% | 11.1% | 11.6% | 3.0% |
| ROA | 6.9% | 6.2% | 9.9% | 5.5% | 3.5% | 3.8% | 7.4% | 6.9% | 5.9% | 5.5% | 0.6% | 4.0% | 4.2% | 1.1% |
| Debt ratio | 38.0% | 41.8% | 42.2% | 55.0% | 54.6% | 54.9% | 51.4% | 54.5% | 52.5% | 60.2% | 63.1% | 63.8% | 63.5% | 62.5% |
Show table：EPS
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS（¥） | 364.87 | 352.61 | 654.20 | 462.57 | 339.96 | 132.00 | 273.85 | 294.74 | 283.62 | 323.36 | 44.72 | 328.59 | 385.71 | 106.66 |
Source: EDINET annual securities reports
TOWA PHARMACEUTICAL CO.,LTD. statutory filings
⚠️ These are in Japanese only. The annual securities report is an FSA statutory filing with no English requirement, and in practice essentially none are filed in English. Links go to the originals on EDINET.
About TOWA PHARMACEUTICAL CO.,LTD. filings
Where can I download TOWA PHARMACEUTICAL CO.,LTD. (4553) earnings reports?
Directly from this page. Quarterly earnings reports (kessan tanshin) and results presentations are filed with the Tokyo Stock Exchange via TDnet; the links point to the original PDFs. This site does not host or redistribute the files.
Are these official English filings or translations?
Official. Since April 2025 the Tokyo Stock Exchange requires Prime Market companies to disclose in English and Japanese simultaneously, so these are the documents the company itself filed. Nothing on this site is machine-translated.
Why are the annual reports in Japanese only?
The yuka shoken hokokusho (annual securities report) is a statutory filing under the Financial Instruments and Exchange Act, submitted to the Financial Services Agency through EDINET. Unlike exchange disclosures it carries no English requirement, and in practice essentially none are filed in English. We link to the Japanese originals rather than pretending an English version exists.
Do Japanese companies still file quarterly reports?
Not as a statutory filing — the quarterly report was abolished in the 2024 amendment to the Financial Instruments and Exchange Act. Quarterly performance is now covered by the kessan tanshin under exchange rules, with the semi-annual report and the annual securities report remaining as statutory filings.
Why only about a month of disclosures?
⚠️ TDnet retains only 31 days and older disclosures cannot be retrieved from the source. This site fetches daily and accumulates, so the covered period grows from here. Statutory filings on EDINET can be fetched retroactively, so those cover two years.
Other Japanese listed companies: Japan stock filings index. This site does not provide investment advice.